Kufstein

Researchers are evaluating the effectiveness of camizestrant compared to standard endocrine therapy in patients with early breast cancer that is estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-). These patients have an intermediate or high risk of cancer recurrence and have already completed local treatments such as surgery and possibly chemotherapy, alongside at least 2 years and up to 5 years of standard adjuvant endocrine therapy. The study is a Phase III, open-label trial designed to assess outcomes over a long term. Participants will be randomly assigned to receive either camizestrant, an oral selective estrogen receptor degrader, or one of several standard endocrine therapies including tamoxifen, anastrozole, letrozole, or exemestane, administered according to local approved guidelines. The treatment duration for both groups is planned to last 60 months. Eligible patients may have previously used CDK4/6 inhibitors, and the study will specifically include those with intermediate or high risk of recurrence as determined by clinical and biological markers. During the study, participants will be monitored for up to 10 years from the last patient's randomization to evaluate invasive breast cancer-free survival. Additional outcomes include invasive disease-free survival, distant relapse-free survival, overall survival, safety, and clinical outcome assessments. The study involves ongoing assessments of health status, treatment effects, and safety to determine the long-term benefits and risks of camizestrant compared to standard therapies.

Chronic lymphocytic leukemia (CLL) has long been considered incurable, except in some patients who can undergo stem cell transplants. Advances such as chemoimmunotherapy with FCR (fludarabine, cyclophosphamide, rituximab) have helped some patients remain relapse-free for up to 10 years. Newer treatments like BTK and Bcl2 inhibitors, along with improved understanding of disease factors, show promise but their long-term effects on progression-free survival, cure rates, and safety are not fully known. This trial is the first nationwide registry in Austria to systematically document CLL patients' medical and treatment data. This registry follows multiple centers in Austria, collecting patient information from medical charts without requiring extra diagnostic or treatment procedures. Data includes patient characteristics, genetics, disease progression, treatments, outcomes, and side effects over time. Participation does not interfere with usual care, and confidentiality is ensured by assigning unique patient numbers. Patients aged 18 and older with CLL will have their routine medical data tracked longitudinally until death or loss to follow-up. Researchers will evaluate general patient traits, genetic profiles, treatment needs, concomitant illnesses, types of therapies, patient outcomes, and toxicities over a 7-year period. No additional visits or procedures are required beyond regular clinical care and chart reviews.

Researchers are evaluating a new patient-reported outcome (PRO) tool designed to detect infections in adults with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who have secondary immunodeficiency (SID). The study aims to improve infection detection and understand how quality of life changes during treatment for these hematological conditions. It is an observational, multicenter study involving participants from Germany and Austria. Participants will use a mobile app daily to report infection-related symptoms through electronic PRO (ePRO) questionnaires. They will also complete quality of life questionnaires every 1.5 months. Study visits occur every three months to collect clinical data including treatment updates, disease staging, and infection history. The app uses push reminders to encourage daily symptom reporting and integrates real-time data tracking. Throughout the study, researchers will monitor the accuracy of the PRO tool in identifying infections confirmed by clinicians. They will assess quality of life changes over time using validated questionnaires specific to MM and CLL. The study also explores if PRO-detected infections lead to starting immunoglobulin replacement therapy and its effects on quality of life. Participation lasts up to one year, with ongoing safety monitoring and regular data collection.

Breast cancer is the most common cancer among women worldwide, with over 5,000 new cases diagnosed annually in Austria. At diagnosis, 5% to 10% of these patients already have distant metastases, and metastasis can develop later in many others depending on lymph node involvement. This study is the first Austrian-wide medical registry to systematically document metastatic breast cancer, aiming to answer epidemiological and treatment-related questions by collecting detailed patient and tumor data. The registry collects both prospective and retrospective data from multiple centers across Austria. It records all tumor characteristics, medical histories, and treatment sequences in anonymized form. The study assesses initial disease progression, tumor characteristics, treatment strategies, and survival outcomes over time. It also evaluates the distribution and characteristics of metastatic breast cancer in male patients and analyzes survival rates at 1, 2, and 5 years after metastasis diagnosis. Participants provide data on histological and radiological evidence of metastases, tumor subtype, treatment history, and disease progression. Researchers monitor overall survival and the frequency of prognostic factors for metastatic breast cancer over a 10-year period. The registry also tracks the influence of gender on treatment approaches and the response to therapies in real-life settings. This comprehensive documentation supports understanding of metastatic breast cancer in Austria and informs future treatment strategies.